CV Date	11/02/2022

Part A. PERSONAL INFORMATION

First Name *	Javier		
Family Name *	García Castro		
Sex *	Male	Date of Birth *	28/02/1971
ID number Social Security, Passport *	05413749D	Phone Number *	918223288
URL Web			
Email Address	jgcastro@isciii.es		
Researcher's identification number	Open Researcher and Contributor ID (ORCID) *	0000-0001-7604-1640	
	Researcher ID	H-5274-2011	
	Scopus Author ID	6603560697	

* Mandatory

A.1. Current position

Job Title	Investigador Científico (Staff researcher)		
Starting date	2016		
Institution	Instituto de Salud Carlos III ("Carlos III" National Institute of Health)		
Department / Centre			
Country		Phone Number	
Keywords	Cell biology; Gene therapy; Cancer		

A.2. Previous positions (Research Career breaks included)

Period	Job Title / Name of Employer / Country
2009 - 2016	Científico titular / Instituto de Salud Carlos III
2007 - 2009	Director del Área de Células Madre Mesenquimales / Banco Andaluz de Células Madre
2004 - 2007	Jefe de grupo / Hospital Infantil Universitario Niño Jesús
2002 - 2004	Jefe de línea / Centro Nacional de Biotecnología
2001 - 2002	Investigador postdoctoral / Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas
1996 - 2001	Investigador predoctoral / Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas

A.3. Education

Degree/Master/PhD	University / Country	Year
Doctor en Ciencias Biológicas (PhD in Biology)	Universidad Complutense de Madrid (Complutense University)	2001

A.4. General quality indicators of scientific production

Number of articles: 77
First quartile (Q1): 50 (67,5%)
Accumulating impacts: 339,51
Number of citations: 6447

h-index: 36
RG score: 39.81

Part C. RELEVANT ACCOMPLISHMENTS

C.1. Most important publications in national or international peer-reviewed journals, books and conferences

AC: corresponding author. (nº x / nº y): position / total authors. If applicable, indicate the number of citations

1 **Scientific paper**. Manuel Hermida-Prieto; Javier Garcia-Castro; Luis Mariñas-Pardo. (2/3). 2021. Systemic treatment of immune-mediated keratoconjunctivitis sicca with allogeneic stem cells improves the schirmer tear test score in a canine spontaneous model of disease 2/3 J Clin Med (IF: 4,24; Q2). 10-24, pp.5981.

2 **Scientific paper**. Stefano Gambera; Ana Patiño-Garcia; Arantzazu Alfranca; Javier Garcia-Castro. 2021. RGB-Marking to Identify Patterns of Selection and Neutral Evolution in Human Osteosarcoma Models. (4/4) Cancers (IF: 5,96; Q1). 13-9, pp.2003.

3 **Scientific paper**. Alvaro Morales-Molina; Stefano Gambera; Angela Leo; Javier García-Castro. 2021. Combination immunotherapy using G-CSF and oncolytic virotherapy reduces tumor growth in osteosarcoma (4/4) J Immunother Cancer. (IF: 13,75 ; Q1). 9-3, pp.e001703.

4 **Scientific paper**. Ana Judith Perisé-Barrios; Beatriz Davinia Tomeo-Martín; Pablo Gómez-Ochoa; et al;. 2021. Humoral responses to SARS-CoV-2 by healthy and sick dogs during the COVID-19 pandemic in Spain. (11/12) Vet Res. (IF: 3.35; Q1/D1). 52-1, pp.22.

5 **Scientific paper**. 2020. Sarcoma treatment in the era of molecular medicine (10/42) EMBO Molecular Medicine (IF: 10.36; Q1/D1). 12-11, pp.e11131.

6 **Scientific paper**. Ana Gómez; David Sardón; Teresa Cejalvo; Fernando Vázquez; Javier García-Castro; Ana Judith Perisé-Barrios. (5/6). 2020. Biodistribution Analysis of Oncolytic Adenoviruses in Canine Patient Necropsy Samples Treated with Cellular Virotherapy Mol Ther Oncolytics (IF: 4.77; Q2). 18, pp.525-534.

7 **Scientific paper**. A Morales-Molina; M A Rodriguez-Milla; A Gimenez-Sanchez; A J Perise-Barrios; J Garcia-Castro (AC). (5/5). 2020. Cellular Virotherapy Increases Tumor-Infiltrating Lymphocytes (TIL) and Decreases their PD-1+ Subsets in Mouse Immunocompetent Models Cancers (IF: 6.43; Q1). 12-7, pp.1920.

8 **Scientific paper**. MA Rodriguez-Milla; A Morales-Molina; AJ Perisé-Barrios; T Cejalvo; J Garcia-Castro (AC). (5/5). 2020. AKT and JUN are differentially activated in mesenchymal stem cells after infection with human and canine oncolytic adenoviruses Cancer Gene Therapy (IF: 3.99; Q1).

9 **Scientific paper**. José A. López-Martín; Lucas Moreno; Álvaro Lassaletta; et al;. 2020. First-in-Human, First-in-Child Trial of Autologous MSCs Carrying the Oncolytic Virus Icovir-5 in Patients with Advanced Tumors (12/13) Mol Ther. (IF: 11,45; Q1). 28-4, pp.1033-1042.

10 **Scientific paper**. Rafael Moreno; Carlos Alberto Fajardo; Marti Farrera-Sal; Ana Judith Perisé-Barrios; Alvaro Morales-Molina; Ahmed Abdullah Al-Zaher; Javier García-Castro; Ramon Alemany. (7/8). 2019. Enhanced Antitumor Efficacy of Oncolytic Adenovirus-loaded Menstrual Blood-derived Mesenchymal Stem Cells in Combination with Peripheral Blood Mononuclear Cells Mol Cancer Ther. (IF: 5.76; Q1). 18-1, pp.127-138.

11 **Scientific paper**. R Moreno; C Fajardo; M Farrera-Sal; A J Perisé-Barrios; A Morales-Molina; A Abdullah Al-zher; J Garcia-Castro; R Alemany. (7/8). 2019. Enhanced Antitumor Efficacy of Oncolytic Adenovirus–loaded Menstrual Blood–derived Mesenchymal Stem Cells in Combination with Peripheral Blood Mononuclear Cells Mol Cancer Ther. (IF: 5.76; Q1). 18-1, pp.127-138.

12 **Scientific paper**. Villanueva AA; Puvogel S; Lois P; et al; García-Castro J; Palma V. (9/12). 2019. The Netrin-4/Laminin B1/Neogenin-1 complex mediates migration in SK-N-SH neuroblastoma cells.Cell adhesion & migration (IF: 4.38; Q2). 13-1, pp.33-40. ISSN 1933-6918.

13 **Scientific paper**. Gambera S; Abarrategi A; González-Camacho F; Morales-Molina Á; Roma J; Alfranca A; García-Castro J (AC). (7/7). 2018. Clonal dynamics in osteosarcoma defined by RGB marking.Nature communications (IF: 13.61; Q1/D1). 9-1, pp.3994.

14 **Scientific paper**. Marinas-Pardo, Luis; Garcia-Castro, Javier; Rodriguez-Hurtado, Isabel; Isabel Rodriguez-Garcia, Maria; Nunez-Naveira, Laura; Hermida-Prieto, Manuel. (2/6). 2018. Allogeneic Adipose-Derived Mesenchymal Stem Cells (Horse Allo 20) for the Treatment of Osteoarthritis-Associated Lameness in Horses: Characterization, Safety, and Efficacy of Intra-Articular Treatment Stem Cells and Development (IF: 3.47; Q2). 27-17, pp.1147-1160.

15 **Scientific paper**. Morales-Molina Á; Gambera S; Cejalvo T; Moreno R; Rodríguez-Milla MÁ; Perisé-Barrios AJ; García-Castro J (AC). (7/7). 2018. Antitumor virotherapy using syngeneic or allogeneic mesenchymal stem cell carriers induces systemic immune response and intratumoral leukocyte infiltration in mice.Cancer immunology, immunotherapy (IF: 4.78; Q1). 67, pp.1589-1602. ISSN 0340-7004.

16 **Scientific paper**. Cejalvo, Teresa; Perise-Barrios, Ana Judith; del Portillo, Isabel; et al; Garcia-Castro, Javier (AC). (12/12). 2018. Remission of Spontaneous Canine Tumors after Systemic Cellular Viroimmunotherapy Cancer Research (IF: 9.88; Q1/D1). 78.

17 **Scientific paper**. Gambera S; Abarrategi A; Rodríguez-Milla MA; Mulero F; Menéndez ST; Rodriguez R; Navarro S; García-Castro J (AC). (8/8). 2018. Role of AP-1 complex in phenotype of human osteosarcomas generated from mesenchymal stem cells.Stem cells (IF: 6.52; Q1).

18 **Scientific paper**. Abarrategi, Ander; Gambera, Stefano; Alfranca, Arantzazu; et al; Garcia-Castro, Javier (AC). (13/13). 2018. c-Fos induces chondrogenic tumor formation in immortalized human mesenchymal progenitor cells Scientific Reports (IF: 4.57; Q1). 8-1, pp.15615. ISSN 2045-2322.

C.3. Research projects and contracts

1 **Project**. Ensayo clínico en fase I con células T memoria expresando un receptor quimérico antigénico con especificidad NKG2D en niños, adolescentes y adultos jóvenes con sarcoma avanzado. (Hospital Universitario La Paz). 01/01/2020-31/12/2024. 799.997 €.

2 **Project**. CAR T therapy estrategies for pediatric sarcomas, preclinical and clinical studies. Fondo de Investigaciones Sanitarias (PI20/00040). (Instituto de Salud Carlos III). 01/01/2021-31/12/2023.

3 **Project**. Liquid biopsy in pediatric sarcomas: deciphering the predictive potential of circulating tumor DNA and of tumor exosomes for early detection of relapses.. (Hospital Universitari Vall d'Hebron). 01/01/2020-31/12/2022. 295.000 €.

4 **Project**. Terapias avanzadas de precisión en regeneración y reparación celular y tisular. (Red AvanCell; B2017/BMD-3692); (Advanced therapies in cellular and regenerative medicine). Comunidad de Madrid. (Red AvanCell; B2017/BMD-3692).. (Instituto de Salud Carlos III ("Carlos III" National Institute of Health)). 01/01/2018-31/12/2021. 956.086 €.

5 **Project**. Optimización de la viroinmunoterapia Celyvir como tratamiento de tumores pediátricos (Refinement of Celyvir viroimmunotherapy as pediatric tumors treatment). Fondo de Investigaciones Sanitarias (PI17/00013). (Instituto de Salud Carlos III ("Carlos III" National Institute of Health)). 01/01/2018-31/12/2020. 127.000 €.

6 **Project**. Activación de células progenitoras mesenquimales como nueva inmunoterapia frente al cáncer (Activation of mesenchymal progenitor cells as a new antitumoral immunotherapy). Fondo de Investigaciones Sanitarias (PI14CIII/00005). (Instituto de Salud Carlos III ("Carlos III" National Institute of Health)). 01/01/2015-31/12/2017.

7 **Project**. MPY 1052/12, Una nueva generación de medicamentos celulares más eficaces y seguros (CELLCAM) (A new generation of cellular medicines more effective and safer). Comunidad de Madrid. (Instituto de Salud Carlos III ("Carlos III" National Institute of Health)). 01/03/2012-01/03/2016.

8 **Project**. Desarrollo de un nuevo fármaco basado en células madre mesenquimales para el tratamiento de caballos con osteoartritis (ABS–20140074 / IDI-20140599) (Development of a new drug based on mesenchymal stem cells for the treatment of horses with osteoarthritis). CDTI (Centro para el Desarrollo Tecnológico Industrial). Javier García Castro. (Centauri Biotech S.L.). 01/09/2014-01/09/2015. 323,38 €.

9 **Project**. PI11/00377, Biología celular de los osteosarcomas (Cell biology of osteosarcomas). Fondo de Investigaciones Sanitarias (PI11/00377). (Instituto de Salud Carlos III ("Carlos III" National Institute of Health)). 01/01/2012-31/12/2014.

10 **Project**. Ensayo clínico en fase I con células T memoria expresando un receptor quimérico antigénico con especificidad NKG2D en niños, adolescentes y adultos jóvenes con sarcoma avanzado. (Hospital Universitario La Paz). From 2020. €.

11 **Project**. Ensayo clínico de viabilidad de la combinación de AloCelyvir con quimioterapia y radioterapia para el tratamiento de niños y adolescentes con tumores sólidos extra-craneales en recaída o refractarios (nº EudraCT 2019-001154-26). (Hospital Infantil Universitario Niño Jesús). From 2019. €.

12 **Project**. Ensayo clínico de seguridad y eficacia de infusiones repetidas de CELYVIR en niños y adultos con tumores sólidos metastásicos y refractarios)ClinicalTrials.gov Identifier: NCT01844661). (Hospital Infantil Universitario Niño Jesús). From 2012. €.